Objective: This systematic review was conducted to summarize the use of circulating tumour cell (CTC) detection as a prognostic indicator in gastric cancer and hepatocellular carcinoma (HCC).
Introduction
Cancer metastasis is a complex process responsible for most of the cancer-related mortality. 1 In nonmetastatic (M0) patients, clinical studies have isolated strong prognostic factors associated with the risk of metastatic relapse, and these factors are routinely used in the clinic to make decisions on adjuvant treatments. 1 At present, adjuvant chemotherapy is administered blinded to the real dissemination status of cancer cells in patients, in turn severely compromising the efficacy of such treatment modalities. Circulating tumour cells (CTCs) in blood and disseminated tumour cells (DTCs) in bone marrow have now been characterized as the two major mediators of cancer metastasis at the intravasation and postextravasation steps, respectively. 1 Gastric cancer and hepatocellular carcinoma (HCC) are the most frequent malignancies worldwide, accounting for approximately 6% of all human cancers, and they are associated with an extensive disease burden. 2,3 Although many advances have been made regarding the clinical diagnosis and management of these cancers, the prognosis remains poor partly because of the lack of knowledge regarding the underlying cellular mechanisms that contribute to the onset and progression of HCC and gastric cancer.
Recent technological improvements have allowed for the detection and characterization of CTCs in gastrointestinal cancers, but the results have largely been heterogeneous. 4, 5 CTC detection techniques are mainly based on isolating cells with epithelial markers from mesenchymal-derived compartments; 6 two steps are generally used: primary enrichment, followed by DTC/CTC detection. None of the currently available techniques have a 100% yield for CTC purification, and the use of multipleantigen selection has not yet demonstrated clear superiority over single-antigen selection. 6, 7 Moreover, high discrepancy rates can be observed using different antibodies against the same membranous marker. 7 The other compounding factor of the current detection techniques is that molecular detection of CTCs relies on the detection of mRNA, which is related either to epithelial function or to specific cancer hallmarks, such as telomerase activity. Both target mRNA and primers used for the amplification step are heterogeneous among studies, which are generally monocentric. 5 It has been recently reported that for CTC/DTC detection in colorectal cancer, more than 20 different targets were assessed, alone or in combination, in 31 molecular studies conducted in more than 25 different single centers. 5 However, the specificity of these molecular techniques is doubtful, as nonspecific expression of epithelial markers has been reported in lymphoid cells activated by cancer-related systemic inflammation. 8 The next step involving cytological detection of CTCs relies on the immunostaining of the CTCs using epithelial antigens thought to be expressed by carcinoma cells. The standardized CELLSEARCH Õ system (Veridex, South Raritan, NJ, USA), 9 which has become the most commonly used CTC detection system over the past few years, enriches the sample cells that have the epithelial cell adhesion molecule, using antibody-coated magnetic beads, and labels the cells with a fluorescent nucleic acid dye, 4',6diamidino-2-phenylindole.
Fluorescently labelled monoclonal antibodies specific for leucocytes (cluster of differentiation [CD]45allophycocyan) and epithelial cells (cytokeratin [CK]8, CK18, CK19-phycoerythrin) are used to distinguish epithelial cells from leucocytes. Beyond epithelial staining, cytological detection methods allow the optical control of stained cells 10 in order to distinguish cancer cells from activated lymphoid cells. This final validation step of cell morphology is time-consuming, hardly automatable, and relies on expert cytologists and/or technicians and whether they use a standardized classification consensus. 11 There are no clear recommendations for the efficacy and accuracy of available detection methods, or the relevance of the quantitative estimation of CTCs in predicting treatment outcome and/or prognosis in HCC patients. Hence, the objective of the current study was to perform a systematic review of published results to assess the different cytology-based CTC detection techniques, given their homogeneity and obvious advantage of demonstrated reproducibility, in patients with gastric cancer and HCC.
Materials and methods

Data sources and search strategy
Clinical studies were identified via Ovid MEDLINE Õ (1980 to November 2012), Ovid EMBASE Õ (1980 to November 2012), SCOPUS (1996 to June 2012), Web of Science databases including Science Citation Index Expanded (1996 to present), Conference Proceedings Citation Index-Science (1990 to present), Database of Abstracts of Reviews of Effects (Issue 3 of 4 July 2012), Cochrane Central Register of Controlled Trials (Issue 3 of 4 July 2012) and the ClinicalTrials.gov website (up to November 2012). Both database-specific controlled vocabulary and general free text terms were used to maximize retrieval. The MeSH terms used were gastric cancer, hepatocellular carcinoma, circulating tumor cells (and circulating tumour cells), disseminated tumor cells (and disseminated tumour cells), circulating tumor cells detection (and circulating tumour cells detection) and micrometastasis. Hand searching of key article reference lists was used to locate additional relevant articles. Eligibility assessment and data abstraction were both performed independently in an unblinded standardized manner by two independent reviewers (P.G. and S-C.J.).
Inclusion and exclusion criteria
Searches were limited to literature published in English, those available as full text (abstract-only reports were excluded) and conducted in humans. Results from all searches were combined and duplicates were removed. Studies were considered eligible if they met the following criteria: (i) the study design was described; (ii) the number of patients included, and their sex and mean age, was stated; (iii) a description of the type of CTC detection technique used, the CTC detection rate and the clinical significance was included. Trials where a particular endpoint was reported only in a single study were not excluded from the final analyses. Studies with fewer than 20 patients or without an outcome analysis were not included. Exclusion was done following the Quality of Reporting of Meta-analyses (QUOROM) recommendations. 12 
Data extraction, synthesis and analysis
The following data were independently extracted: study characteristics (first author, year of publication, country of origin); sample size; molecular marker assessed; CTC detection rate; and correlation of positive CTC detection to clinical significance. When available, the outcomes (distant metastasis-free survival [DMFS] and/or overall survival [OS]) in the collected manuscripts were synthesized and formed the basis for further analysis, which was done following recommendations from The Cochrane Collaboration and the QUORUM recommendations. 12 Impact on survival was not systematically assessed in multivariate analysis.
Statistical analyses
Statistical analysis was performed by an expert statistician (L.B.) using the SPSS Õ software package, version 19.0 (SPSS Inc., Chicago, IL, USA) for Windows Õ . Descriptive statistics were used to provide a summary description of the general data (study design), patients (number of included patients, mean age, sex), type of detection technique used, CTC detection rate and clinical significance. All results reported were based on a relatively small sample size.
Potential publication bias was not tested with a funnel plot or other corrective analytical methods as the number of nonheterogeneous studies included in the review was small (n ¼ 16). There were insufficient data available to use quantitative analyses to summarize the data. However, the overall quality of the evidence for each outcome was assessed using an adapted Grades of Recommendation, Assessment, Development and Evaluation approach, as recommended by the Cochrane Back Review Group. 12 The quality of the evidence for a specific outcome was based on the study design, risk of bias, consistency of results, directness (generalizability), precision (sufficient data) and potential bias for the reporting of results across all studies that measured that particular outcome.
Results
Search results and assessment of heterogeneity
A flow diagram that summarizes the results of the detailed literature search and study selection procedure is presented in Figure 1 . Studies were excluded based on QUOROM recommendations. Fifteen gastric cancer (Table 1) [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] and 10 HCC (Table 2) [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] studies, with a total of 793 and 577 patients, respectively, met the specific inclusion criteria for this analysis.
Risk of bias in included studies
The 12 criteria recommended by the Cochrane Back Review Group were used to assess the risk of bias among the 25 included studies. The number of criteria met varied from 1/12 to 2/12 with a mean score of 1.5/12. All of the studies (25/25) were considered to have a high risk of bias. None of the included studies had an adequate description of withdrawals and drop outs. None of the studies reported or appeared to use an intention-to-treat analysis (Figure 2 ). Heterogeneity and potential bias among the studies prevented any statistical interpretation; however, their possible applications as new biomarkers are discussed.
CTC detection in gastric cancer
The presence of CTCs in patients with gastric cancer has been studied in several small studies (Table 1) . [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] However, it is of note that no clear conclusion could be drawn from these heterogeneous studies, which were often underpowered. Among the several molecular markers tested (e.g. CK18, CK19, CK20, carcinoembryonic antigen, human telomerase reverse transcriptase), none demonstrated a clear and confirmed superiority over the others. [13] [14] [15] [16] [17] [18] [19] The CTC detection rate was related to the surgical manoeuvres during the surgical removal of excisable cancers, and was initially correlated with poor survival. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Some reports have also focused on the patient's blood stored for autologous transfusion during surgery by testing CTCs using various techniques after removal from blood and undergoing freezing, filtering and irradiation. 19 
CTC detection in HCC
Current treatment strategies for nonmetastatic HCC incorporate chemoembolization, alcoholization, liver allograft or liver resection. It is important to note that except for in cases where CTC release is induced by a surgical procedure, 29 biomarkers for metastatic progression are vital since the incidence of relapse is significantly high in this cohort. Alpha fetoprotein (AFP) mRNA was the first such marker that was found to have an association with the disease stage; 29, 30 since then several CTC molecular detection studies have been published (Table 2) . [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Of note, the clinical results reported in these studies were heterogeneous, whereas AFP mRNA specificity was reported. 37 
Discussion
In general, the results of investigations into the use of molecular tools for CTC detection in gastric cancer and HCC, based mainly on the CTC epithelial phenotype, have been very heterogeneous. 3, 6, 16, 22 It has not been possible to assess their relative importance and clinical significance because the data available are currently so limited. Most of the studies published in the literature reported positive results (i.e. there was an association between CTC detection and clinical outcome), but publication bias seriously distorts any attempts, including those of published meta-analyses, to accurately estimate the effect of CTC detection. 5 One may hypothesize that molecular techniques were mostly developed by isolated academic teams without any strong commitment to standardize the various techniques. Cytological detection studies were initially academically driven and provided interesting insights into the dissemination process, particularly the genetic evolution from the primary tumour to DTCs to overt macrometastases. 9,10 In most of the studies included in this current analysis, the CTC detection rate was related to the surgical manoeuvres during the surgical removal of excisable cancers, which in turn was initially correlated with poor survival. 18, 22 Surgery-related CTC release was also shown in another study, even though postoperative CTC positivity was associated with an improved prognosis. 41 Using the CELLSEARCH Õ system, the CTC detection rate varied between 14% and 55% in 14 nonmetastatic and 27 metastatic patients, respectively (!2 CTCs/ 7.5 ml). 42 A Japanese group reported an association between CTC detection and chemotherapeutic efficacy in 52 patients with gastric cancer and advanced metastatic disease treated with different chemotherapy regimens. 41 High CTC counts during treatment (!4 CTCs/7.5 ml at 2-4 weeks after the start of treatment) were associated with a poor outcome (progression-free survival [PFS], 1.4 versus 4.9 months; OS, 3.5 versus 11.7 months, in comparison with patients with <4 CTCs/7.5 ml). 43 Technical heterogeneity inherent in the various academic methods for CTC detection resulted in the development of the semi-automated and standardized CELLSEARCH Õ system, which has benefited large industry-sponsored clinical studies. This system became the gold standard for CTC detection in 2011 and is currently being used routinely in exploratory studies of several gastrointestinal cancer types. The validation of CTC changes as a recognized surrogate endpoint for PFS will require data that not only demonstrate that CTC changes Figure 2 . The risk of bias among the 25 included studies as assessed using the 12 criteria recommended by the Cochrane Back Review Group. 'þ' and 'À' indicate that all of the studies included for the tumor type conformed or did not conform, respectively, to that particular criteria; '?' indicates that based on the information extracted, it could not be verified whether that particular criteria was fulfilled by all of the studies. ITT, intention-to-treat. are prognostic of PFS, but also that the effect of treatment on CTC changes correlate with that of PFS; this will require the accumulation of data into a large metaanalysis. 44 Future research into the use of DTC and CTC detection in gastric cancer and HCC will need to focus on the following issue. It is imperative that future research endeavours to focus on incorporating quantitative cytological-based CTC count detection techniques, along with the advances made in discovering new haematopoietic markers, including tumour genotyping and microRNA analysis. However, the prospective benefit of using CTC as a quantitative marker has been slightly diminished with the discovery of gene mutations that can be equivalently used as diagnostic and prognostic markers. 45 The benefit of detecting CTCs is that it yields similar information as would normally be provided by a biopsy; this gives it the added advantage of providing useful information regarding the pathogenetic mechanism of solid tumours. The qualitative analysis of the presence of CTCs, as highlighted in this current review, may thus help in deciding on the best treatment regimen to adopt and allow for an assessment of the effectiveness of the selected treatment strategy.
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